CHOK1SV Cells being processed

Industry-Leading Technologies Combined

A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and BioWa.  The new cell line, Potelligent® CHOK1SV®, combines the advantages of Lonza’s proprietary GS Gene Expression System® with the power of BioWa’s engineered glycosylation technology.

Scientists at Kyowa Hakko Kogyo Co. Ltd. (now, Kyowa Hakko Kirin Co., Ltd.) demonstrated that an antibody with a reduced fucose content in glycan moieties exhibited much higher antibody dependent cellular cytotoxicity (ADCC) activity compared to a normally fucosylated antibody. They confirmed that the mechanism behind the enhanced ADCC of a low / no-fucose antibody was its increased affinity to FcγRIIIa (CD16), the major Fc receptor for ADCC in humans. A cell line with knockout of both alleles for the gene responsible for fucose addition (α1,6-fucosyltransferase; FUT8) can take advantage of this phenomenon, producing Potelligent® mAbs with enhanced ADCC activity.

Creation of this new host cell line that combines the powerful Potelligent® Technology with Lonza’s pre-eminent host cell line, CHOK1SV®, is significant advancement in gene expression technology.  An FUT8 double gene knock out variant of CHOK1SV® has therefore been developed for therapeutic protein expression. This new host cell line has been called Potelligent® CHOK1SV® Cell Line. 

As with traditional CHOK1SV®, Potelligent® CHOK1SV® grows in single cell suspension culture and in chemically defined, animal component-free media. Both the Potelligent® CHOK1SV® host cell line and recombinant cell lines derived from Potelligent® CHOK1SV® exhibit good growth characteristics as shown below.

Download our Potelligent® CHOK1SV® Brochure  for more information.

Figure 1 and 2:  Examples of growth of Potelligent® CHOK1SV® derived cell lines at routine subculture.